ID   S22A8_HUMAN             Reviewed;         542 AA.
AC   Q8TCC7; B4DPH7; F5GWA8; F5H5J1; O95820; Q59EW9; Q96TC1;
DT   23-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 1.
DT   28-JUN-2023, entry version 161.
DE   RecName: Full=Organic anion transporter 3;
DE            Short=hOAT3 {ECO:0000303|PubMed:14586168};
DE   AltName: Full=Organic anion/dicarboxylate exchanger;
DE   AltName: Full=Solute carrier family 22 member 8;
GN   Name=SLC22A8; Synonyms=OAT3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=10049739; DOI=10.1006/bbrc.1998.9978;
RA   Race J.E., Grassl S.M., Williams W.J., Holtzman E.J.;
RT   "Molecular cloning and characterization of two novel human renal organic
RT   anion transporters (hOAT1 and hOAT3).";
RL   Biochem. Biophys. Res. Commun. 255:508-514(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RA   Cha S., Sekine T., Kanai Y., Endou H.;
RT   "Molecular cloning and characterization of human organic anion transporter
RT   3.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, TISSUE SPECIFICITY, TRANSPORTER ACTIVITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=11306713; DOI=10.1124/mol.59.5.1277;
RA   Cha S.H., Sekine T., Fukushima J.I., Kanai Y., Kobayashi Y., Goya T.,
RA   Endou H.;
RT   "Identification and characterization of human organic anion transporter 3
RT   expressing predominantly in the kidney.";
RL   Mol. Pharmacol. 59:1277-1286(2001).
RN   [8]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11912245; DOI=10.1681/asn.v134866;
RA   Motohashi H., Sakurai Y., Saito H., Masuda S., Urakami Y., Goto M.,
RA   Fukatsu A., Ogawa O., Inui K.;
RT   "Gene expression levels and immunolocalization of organic ion transporters
RT   in the human kidney.";
RL   J. Am. Soc. Nephrol. 13:866-874(2002).
RN   [9]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11907186; DOI=10.1124/jpet.301.1.293;
RA   Kimura H., Takeda M., Narikawa S., Enomoto A., Ichida K., Endou H.;
RT   "Human organic anion transporters and human organic cation transporters
RT   mediate renal transport of prostaglandins.";
RL   J. Pharmacol. Exp. Ther. 301:293-298(2002).
RN   [10]
RP   FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=14586168; DOI=10.1159/000074539;
RA   Bakhiya A., Bahn A., Burckhardt G., Wolff N.;
RT   "Human organic anion transporter 3 (hOAT3) can operate as an exchanger and
RT   mediate secretory urate flux.";
RL   Cell. Physiol. Biochem. 13:249-256(2003).
RN   [11]
RP   FUNCTION.
RX   PubMed=15644426; DOI=10.1124/jpet.104.080366;
RA   Srimaroeng C., Chatsudthipong V., Aslamkhan A.G., Pritchard J.B.;
RT   "Transport of the natural sweetener stevioside and its aglycone steviol by
RT   human organic anion transporter (hOAT1; SLC22A6) and hOAT3 (SLC22A8).";
RL   J. Pharmacol. Exp. Ther. 313:621-628(2005).
RN   [12]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15846473; DOI=10.1007/s11095-005-2503-0;
RA   Tahara H., Shono M., Kusuhara H., Kinoshita H., Fuse E., Takadate A.,
RA   Otagiri M., Sugiyama Y.;
RT   "Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus
RT   monkey kidney.";
RL   Pharm. Res. 22:647-660(2005).
RN   [13]
RP   FUNCTION, TISSUE SPECIFICITY, TRANSPORTER ACTIVITY, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=15864504; DOI=10.1007/s00424-004-1373-3;
RA   Asif A.R., Steffgen J., Metten M., Grunewald R.W., Mueller G.A., Bahn A.,
RA   Burckhardt G., Hagos Y.;
RT   "Presence of organic anion transporters 3 (OAT3) and 4 (OAT4) in human
RT   adrenocortical cells.";
RL   Pflugers Arch. 450:88-95(2005).
RN   [14]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16455804; DOI=10.1124/dmd.105.008375;
RA   Tahara H., Kusuhara H., Maeda K., Koepsell H., Fuse E., Sugiyama Y.;
RT   "Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug
RT   interaction between fexofenadine and probenecid.";
RL   Drug Metab. Dispos. 34:743-747(2006).
RN   [15]
RP   TRANSPORTER ACTIVITY, AND FUNCTION.
RX   PubMed=31553721; DOI=10.1371/journal.pgen.1008208;
RA   Yee S.W., Stecula A., Chien H.C., Zou L., Feofanova E.V., van Borselen M.,
RA   Cheung K.W.K., Yousri N.A., Suhre K., Kinchen J.M., Boerwinkle E.,
RA   Irannejad R., Yu B., Giacomini K.M.;
RT   "Unraveling the functional role of the orphan solute carrier, SLC22A24 in
RT   the transport of steroid conjugates through metabolomic and genome-wide
RT   association studies.";
RL   PLoS Genet. 15:E1008208-E1008208(2019).
RN   [16]
RP   VARIANT VAL-389.
RX   PubMed=12811365; DOI=10.1016/s0009-9236(03)00060-2;
RA   Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T.,
RA   Takane H., Irie S., Kusuhara H., Urasaki Y., Urae A., Higuchi S.,
RA   Otsubo K., Sugiyama Y.;
RT   "Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences
RT   for pravastatin pharmacokinetics.";
RL   Clin. Pharmacol. Ther. 73:554-565(2003).
RN   [17]
RP   VARIANTS SER-149; ARG-260; TRP-277 AND PHE-305, AND CHARACTERIZATION OF
RP   VARIANTS SER-149; ARG-260; TRP-277 AND PHE-305.
RX   PubMed=16291576; DOI=10.1152/ajprenal.00272.2005;
RA   Erdman A.R., Mangravite L.M., Urban T.J., Lagpacan L.L., Castro R.A.,
RA   de la Cruz M., Chan W., Huang C.C., Johns S.J., Kawamoto M., Stryke D.,
RA   Taylor T.R., Carlson E.J., Ferrin T.E., Brett C.M., Burchard E.G.,
RA   Giacomini K.M.;
RT   "The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation
RT   and functional genomics.";
RL   Am. J. Physiol. 290:F905-F912(2006).
CC   -!- FUNCTION: Functions as an organic anion/dicarboxylate exchanger that
CC       couples organic anion uptake indirectly to the sodium gradient
CC       (PubMed:14586168, PubMed:15644426, PubMed:15846473, PubMed:16455804,
CC       PubMed:31553721). Transports organic anions such as estrone 3-sulfate
CC       (E1S) and urate in exchange for dicarboxylates such as glutarate or
CC       ketoglutarate (2-oxoglutarate) (PubMed:14586168, PubMed:15846473,
CC       PubMed:15864504). Plays an important role in the excretion of
CC       endogenous and exogenous organic anions, especially from the kidney and
CC       the brain (PubMed:14586168, PubMed:15846473, PubMed:11306713).
CC       Responsible for the transport of prostaglandin E2 (PGE2) and
CC       prostaglandin F2(alpha) (PGF2(alpha)) in the basolateral side of the
CC       renal tubule (PubMed:11907186). May be involved in the basolateral
CC       transport of steviol, a metabolite of the popular sugar substitute
CC       stevioside (PubMed:15644426). May participate in the detoxification/
CC       renal excretion of drugs and xenobiotics, such as the histamine H(2)-
CC       receptor antagonists fexofenadine and cimetidine, the antibiotic
CC       benzylpenicillin (PCG), the anionic herbicide 2,4-dichloro-
CC       phenoxyacetate (2,4-D), the diagnostic agent p-aminohippurate (PAH),
CC       the antiviral acyclovir (ACV), and the mycotoxin ochratoxin (OTA), by
CC       transporting these exogenous organic anions across the cell membrane in
CC       exchange for dicarboxylates such as 2-oxoglutarate (PubMed:15846473,
CC       PubMed:16455804). Contributes to the renal uptake of potent uremic
CC       toxins (indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-
CC       furanpropionate (CMPF)), pravastatin, PCG, E1S and
CC       dehydroepiandrosterone sulfate (DHEAS), and is partly involved in the
CC       renal uptake of temocaprilat (an angiotensin-converting enzyme (ACE)
CC       inhibitor) (By similarity). May contribute to the release of cortisol
CC       in the adrenals (PubMed:15864504). Involved in one of the
CC       detoxification systems on the choroid plexus (CP), removes substrates
CC       such as E1S or taurocholate (TC), PCG, 2,4-D and PAH, from the
CC       cerebrospinal fluid (CSF) to the blood for eventual excretion in urine
CC       and bile (By similarity). Also contributes to the uptake of several
CC       other organic compounds such as the prostanoids prostaglandin E(2) and
CC       prostaglandin F(2-alpha), L-carnitine, and the therapeutic drugs
CC       allopurinol, 6-mercaptopurine (6-MP) and 5-fluorouracil (5-FU) (By
CC       similarity). Mediates the transport of PAH, PCG, and the statins
CC       pravastatin and pitavastatin, from the cerebrum into the blood
CC       circulation across the blood-brain barrier (BBB). In summary, plays a
CC       role in the efflux of drugs and xenobiotics, helping reduce their
CC       undesired toxicological effects on the body (By similarity).
CC       {ECO:0000250|UniProtKB:O88909, ECO:0000250|UniProtKB:Q9R1U7,
CC       ECO:0000269|PubMed:11306713, ECO:0000269|PubMed:11907186,
CC       ECO:0000269|PubMed:14586168, ECO:0000269|PubMed:15644426,
CC       ECO:0000269|PubMed:15846473, ECO:0000269|PubMed:15864504,
CC       ECO:0000269|PubMed:16455804, ECO:0000269|PubMed:31553721,
CC       ECO:0000303|PubMed:15864504}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=estrone 3-sulfate(out) + glutarate(in) = estrone 3-sulfate(in)
CC         + glutarate(out); Xref=Rhea:RHEA:72151, ChEBI:CHEBI:30921,
CC         ChEBI:CHEBI:60050; Evidence={ECO:0000269|PubMed:14586168,
CC         ECO:0000269|PubMed:15846473, ECO:0000269|PubMed:15864504,
CC         ECO:0000269|PubMed:31553721};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate(out) + estrone 3-sulfate(in) = 2-
CC         oxoglutarate(in) + estrone 3-sulfate(out); Xref=Rhea:RHEA:72399,
CC         ChEBI:CHEBI:16810, ChEBI:CHEBI:60050;
CC         Evidence={ECO:0000269|PubMed:14586168};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate(out) + glutarate(in) = 2-oxoglutarate(in) +
CC         glutarate(out); Xref=Rhea:RHEA:71751, ChEBI:CHEBI:16810,
CC         ChEBI:CHEBI:30921; Evidence={ECO:0000269|PubMed:14586168};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate(out) + urate(in) = 2-oxoglutarate(in) +
CC         urate(out); Xref=Rhea:RHEA:72403, ChEBI:CHEBI:16810,
CC         ChEBI:CHEBI:17775; Evidence={ECO:0000269|PubMed:14586168};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glutarate(in) + taurocholate(out) = glutarate(out) +
CC         taurocholate(in); Xref=Rhea:RHEA:72159, ChEBI:CHEBI:30921,
CC         ChEBI:CHEBI:36257; Evidence={ECO:0000305|PubMed:11306713};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dehydroepiandrosterone 3-sulfate(out) + glutarate(in) =
CC         dehydroepiandrosterone 3-sulfate(in) + glutarate(out);
CC         Xref=Rhea:RHEA:72355, ChEBI:CHEBI:30921, ChEBI:CHEBI:57905;
CC         Evidence={ECO:0000305|PubMed:11306713};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glutarate(in) + prostaglandin F2alpha(out) = glutarate(out) +
CC         prostaglandin F2alpha(in); Xref=Rhea:RHEA:72503, ChEBI:CHEBI:30921,
CC         ChEBI:CHEBI:57404; Evidence={ECO:0000305|PubMed:11907186};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate(in) + prostaglandin F2alpha(out) = 2-
CC         oxoglutarate(out) + prostaglandin F2alpha(in); Xref=Rhea:RHEA:72507,
CC         ChEBI:CHEBI:16810, ChEBI:CHEBI:57404;
CC         Evidence={ECO:0000305|PubMed:11907186};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-carnitine(out) + 2-oxoglutarate(in) = (R)-carnitine(in) +
CC         2-oxoglutarate(out); Xref=Rhea:RHEA:72511, ChEBI:CHEBI:16347,
CC         ChEBI:CHEBI:16810; Evidence={ECO:0000250|UniProtKB:O88909};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-carnitine(out) + glutarate(in) = (R)-carnitine(in) +
CC         glutarate(out); Xref=Rhea:RHEA:72515, ChEBI:CHEBI:16347,
CC         ChEBI:CHEBI:30921; Evidence={ECO:0000250|UniProtKB:O88909};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate(in) + prostaglandin E2(out) = 2-
CC         oxoglutarate(out) + prostaglandin E2(in); Xref=Rhea:RHEA:72499,
CC         ChEBI:CHEBI:16810, ChEBI:CHEBI:606564;
CC         Evidence={ECO:0000305|PubMed:11907186};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glutarate(in) + prostaglandin E2(out) = glutarate(out) +
CC         prostaglandin E2(in); Xref=Rhea:RHEA:72495, ChEBI:CHEBI:30921,
CC         ChEBI:CHEBI:606564; Evidence={ECO:0000305|PubMed:11907186};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glutarate(out) + urate(in) = glutarate(in) + urate(out);
CC         Xref=Rhea:RHEA:72551, ChEBI:CHEBI:17775, ChEBI:CHEBI:30921;
CC         Evidence={ECO:0000269|PubMed:14586168};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate(in) + taurocholate(out) = 2-oxoglutarate(out) +
CC         taurocholate(in); Xref=Rhea:RHEA:72547, ChEBI:CHEBI:16810,
CC         ChEBI:CHEBI:36257; Evidence={ECO:0000305|PubMed:11306713};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2-oxoglutarate(in) + dehydroepiandrosterone 3-sulfate(out) =
CC         2-oxoglutarate(out) + dehydroepiandrosterone 3-sulfate(in);
CC         Xref=Rhea:RHEA:72543, ChEBI:CHEBI:16810, ChEBI:CHEBI:57905;
CC         Evidence={ECO:0000305|PubMed:11306713};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=345 nM for prostaglandin E2 {ECO:0000269|PubMed:11907186};
CC         KM=1.092 uM for prostaglandin F2alpha {ECO:0000269|PubMed:11907186};
CC         KM=9.51 uM for estrone 3-sulfate {ECO:0000269|PubMed:15846473};
CC         KM=3.1 uM for estrone 3-sulfate {ECO:0000269|PubMed:11306713};
CC         KM=70.2 uM for fexofenadine {ECO:0000269|PubMed:16455804};
CC         KM=2.4 uM for cortisol {ECO:0000269|PubMed:15864504};
CC         Vmax=265 pmol/min/mg enzyme with estrone 3-sulfate as substrate
CC         {ECO:0000269|PubMed:15846473};
CC         Vmax=120 pmol/min/mg enzyme with fexofenadine as substrate
CC         {ECO:0000269|PubMed:16455804};
CC   -!- SUBCELLULAR LOCATION: Basolateral cell membrane
CC       {ECO:0000269|PubMed:11306713}; Multi-pass membrane protein
CC       {ECO:0000305}. Note=Localizes on the brush border membrane of the
CC       choroid epithelial cells (By similarity). Localizes to the basolateral
CC       membrane of the proximal tubular cells (PubMed:11306713). Localizes on
CC       the abluminal and possibly, luminal membrane of the brain capillary
CC       endothelial cells (BCEC) (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q9R1U7, ECO:0000269|PubMed:11306713}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q8TCC7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8TCC7-2; Sequence=VSP_022565;
CC       Name=5;
CC         IsoId=Q8TCC7-5; Sequence=VSP_045824;
CC       Name=3;
CC         IsoId=Q8TCC7-3; Sequence=VSP_022562, VSP_022563, VSP_022564;
CC       Name=4;
CC         IsoId=Q8TCC7-4; Sequence=VSP_045272;
CC   -!- TISSUE SPECIFICITY: Strongly expressed in kidney (PubMed:11306713,
CC       PubMed:11912245). Weaker expression in brain and skeletal muscle
CC       (PubMed:11306713). Expressed in adrenal glands (PubMed:15864504).
CC       {ECO:0000269|PubMed:11306713, ECO:0000269|PubMed:11912245,
CC       ECO:0000269|PubMed:15864504}.
CC   -!- SIMILARITY: Belongs to the major facilitator (TC 2.A.1) superfamily.
CC       Organic cation transporter (TC 2.A.1.19) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD19357.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAD92929.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF097491; AAD19357.1; ALT_FRAME; mRNA.
DR   EMBL; AB042505; BAB47393.1; -; mRNA.
DR   EMBL; AK298341; BAG60589.1; -; mRNA.
DR   EMBL; AB209692; BAD92929.1; ALT_INIT; mRNA.
DR   EMBL; AP001858; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC022387; AAH22387.1; -; mRNA.
DR   CCDS; CCDS53643.1; -. [Q8TCC7-5]
DR   CCDS; CCDS53644.1; -. [Q8TCC7-4]
DR   CCDS; CCDS8042.1; -. [Q8TCC7-1]
DR   RefSeq; NP_001171661.1; NM_001184732.1. [Q8TCC7-1]
DR   RefSeq; NP_001171662.1; NM_001184733.1. [Q8TCC7-4]
DR   RefSeq; NP_001171665.1; NM_001184736.1. [Q8TCC7-5]
DR   RefSeq; NP_004245.2; NM_004254.3. [Q8TCC7-1]
DR   RefSeq; XP_011543666.1; XM_011545364.1.
DR   AlphaFoldDB; Q8TCC7; -.
DR   SMR; Q8TCC7; -.
DR   BioGRID; 114777; 23.
DR   IntAct; Q8TCC7; 4.
DR   STRING; 9606.ENSP00000337335; -.
DR   BindingDB; Q8TCC7; -.
DR   ChEMBL; CHEMBL1641348; -.
DR   DrugBank; DB14973; Abrocitinib.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB00787; Acyclovir.
DR   DrugBank; DB00437; Allopurinol.
DR   DrugBank; DB00345; Aminohippuric acid.
DR   DrugBank; DB11901; Apalutamide.
DR   DrugBank; DB09274; Artesunate.
DR   DrugBank; DB00168; Aspartame.
DR   DrugBank; DB05016; Ataluren.
DR   DrugBank; DB11995; Avatrombopag.
DR   DrugBank; DB09060; Avibactam.
DR   DrugBank; DB11817; Baricitinib.
DR   DrugBank; DB03793; Benzoic acid.
DR   DrugBank; DB01053; Benzylpenicillin.
DR   DrugBank; DB14669; Betamethasone phosphate.
DR   DrugBank; DB12151; Brincidofovir.
DR   DrugBank; DB01222; Budesonide.
DR   DrugBank; DB00887; Bumetanide.
DR   DrugBank; DB11751; Cabotegravir.
DR   DrugBank; DB04519; Caprylic acid.
DR   DrugBank; DB01414; Cefacetrile.
DR   DrugBank; DB00833; Cefaclor.
DR   DrugBank; DB01140; Cefadroxil.
DR   DrugBank; DB09008; Cefaloridine.
DR   DrugBank; DB00456; Cefalotin.
DR   DrugBank; DB01326; Cefamandole.
DR   DrugBank; DB01327; Cefazolin.
DR   DrugBank; DB00535; Cefdinir.
DR   DrugBank; DB01329; Cefoperazone.
DR   DrugBank; DB00493; Cefotaxime.
DR   DrugBank; DB00229; Cefotiam.
DR   DrugBank; DB01415; Ceftibuten.
DR   DrugBank; DB01332; Ceftizoxime.
DR   DrugBank; DB01212; Ceftriaxone.
DR   DrugBank; DB00567; Cephalexin.
DR   DrugBank; DB02659; Cholic Acid.
DR   DrugBank; DB01597; Cilastatin.
DR   DrugBank; DB00501; Cimetidine.
DR   DrugBank; DB01147; Cloxacillin.
DR   DrugBank; DB00286; Conjugated estrogens.
DR   DrugBank; DB01380; Cortisone acetate.
DR   DrugBank; DB02527; Cyclic adenosine monophosphate.
DR   DrugBank; DB08912; Dabrafenib.
DR   DrugBank; DB04133; Degraded Cephaloridine.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB14649; Dexamethasone acetate.
DR   DrugBank; DB09213; Dexibuprofen.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB01160; Dinoprost tromethamine.
DR   DrugBank; DB00917; Dinoprostone.
DR   DrugBank; DB08930; Dolutegravir.
DR   DrugBank; DB06211; Doripenem.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB12243; Edaravone.
DR   DrugBank; DB09272; Eluxadoline.
DR   DrugBank; DB09038; Empagliflozin.
DR   DrugBank; DB00584; Enalapril.
DR   DrugBank; DB13874; Enasidenib.
DR   DrugBank; DB00736; Esomeprazole.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB13952; Estradiol acetate.
DR   DrugBank; DB13953; Estradiol benzoate.
DR   DrugBank; DB13954; Estradiol cypionate.
DR   DrugBank; DB13955; Estradiol dienanthate.
DR   DrugBank; DB13956; Estradiol valerate.
DR   DrugBank; DB00655; Estrone.
DR   DrugBank; DB00927; Famotidine.
DR   DrugBank; DB12466; Favipiravir.
DR   DrugBank; DB12265; Fexinidazole.
DR   DrugBank; DB00950; Fexofenadine.
DR   DrugBank; DB00695; Furosemide.
DR   DrugBank; DB01004; Ganciclovir.
DR   DrugBank; DB01241; Gemfibrozil.
DR   DrugBank; DB03553; Glutaric Acid.
DR   DrugBank; DB00536; Guanidine.
DR   DrugBank; DB00999; Hydrochlorothiazide.
DR   DrugBank; DB00741; Hydrocortisone.
DR   DrugBank; DB14538; Hydrocortisone aceponate.
DR   DrugBank; DB14539; Hydrocortisone acetate.
DR   DrugBank; DB14540; Hydrocortisone butyrate.
DR   DrugBank; DB14541; Hydrocortisone cypionate.
DR   DrugBank; DB14542; Hydrocortisone phosphate.
DR   DrugBank; DB14543; Hydrocortisone probutate.
DR   DrugBank; DB14544; Hydrocortisone valerate.
DR   DrugBank; DB00774; Hydroflumethiazide.
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB14568; Ivosidenib.
DR   DrugBank; DB01009; Ketoprofen.
DR   DrugBank; DB00448; Lansoprazole.
DR   DrugBank; DB00654; Latanoprost.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB12070; Letermovir.
DR   DrugBank; DB00650; Leucovorin.
DR   DrugBank; DB00583; Levocarnitine.
DR   DrugBank; DB00601; Linezolid.
DR   DrugBank; DB17083; Linzagolix.
DR   DrugBank; DB00279; Liothyronine.
DR   DrugBank; DB01583; Liotrix.
DR   DrugBank; DB00253; Medrysone.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB01033; Mercaptopurine.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB06710; Methyltestosterone.
DR   DrugBank; DB00788; Naproxen.
DR   DrugBank; DB01051; Novobiocin.
DR   DrugBank; DB16267; Olutasidenib.
DR   DrugBank; DB00198; Oseltamivir.
DR   DrugBank; DB11837; Osilodrostat.
DR   DrugBank; DB01092; Ouabain.
DR   DrugBank; DB03902; Oxalic Acid.
DR   DrugBank; DB00595; Oxytetracycline.
DR   DrugBank; DB00213; Pantoprazole.
DR   DrugBank; DB00642; Pemetrexed.
DR   DrugBank; DB00812; Phenylbutazone.
DR   DrugBank; DB00319; Piperacillin.
DR   DrugBank; DB00554; Piroxicam.
DR   DrugBank; DB01324; Polythiazide.
DR   DrugBank; DB12866; Pradigastat.
DR   DrugBank; DB05804; Prasterone sulfate.
DR   DrugBank; DB00175; Pravastatin.
DR   DrugBank; DB14631; Prednisolone phosphate.
DR   DrugBank; DB05154; Pretomanid.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB00881; Quinapril.
DR   DrugBank; DB00908; Quinidine.
DR   DrugBank; DB00863; Ranitidine.
DR   DrugBank; DB12377; Relebactam.
DR   DrugBank; DB01045; Rifampicin.
DR   DrugBank; DB12457; Rimegepant.
DR   DrugBank; DB01098; Rosuvastatin.
DR   DrugBank; DB04847; Roxadustat.
DR   DrugBank; DB12332; Rucaparib.
DR   DrugBank; DB00936; Salicylic acid.
DR   DrugBank; DB06335; Saxagliptin.
DR   DrugBank; DB01261; Sitagliptin.
DR   DrugBank; DB00139; Succinic acid.
DR   DrugBank; DB11644; Tafamidis.
DR   DrugBank; DB04348; Taurocholic acid.
DR   DrugBank; DB01606; Tazobactam.
DR   DrugBank; DB14126; Tenofovir.
DR   DrugBank; DB09299; Tenofovir alafenamide.
DR   DrugBank; DB00300; Tenofovir disoproxil.
DR   DrugBank; DB00469; Tenoxicam.
DR   DrugBank; DB00624; Testosterone.
DR   DrugBank; DB13943; Testosterone cypionate.
DR   DrugBank; DB13944; Testosterone enanthate.
DR   DrugBank; DB13946; Testosterone undecanoate.
DR   DrugBank; DB00759; Tetracycline.
DR   DrugBank; DB08837; Tetraethylammonium.
DR   DrugBank; DB01685; Topiroxostat.
DR   DrugBank; DB01650; trans-2-hydroxycinnamic acid.
DR   DrugBank; DB08844; Uric acid.
DR   DrugBank; DB00577; Valaciclovir.
DR   DrugBank; DB00313; Valproic acid.
DR   DrugBank; DB00495; Zidovudine.
DR   DrugCentral; Q8TCC7; -.
DR   GuidetoPHARMACOLOGY; 1027; -.
DR   TCDB; 2.A.1.19.34; the major facilitator superfamily (mfs).
DR   GlyCosmos; Q8TCC7; 2 sites, No reported glycans.
DR   GlyGen; Q8TCC7; 2 sites.
DR   iPTMnet; Q8TCC7; -.
DR   PhosphoSitePlus; Q8TCC7; -.
DR   SwissPalm; Q8TCC7; -.
DR   BioMuta; SLC22A8; -.
DR   DMDM; 74730587; -.
DR   jPOST; Q8TCC7; -.
DR   MassIVE; Q8TCC7; -.
DR   PaxDb; Q8TCC7; -.
DR   PeptideAtlas; Q8TCC7; -.
DR   ProteomicsDB; 24057; -.
DR   ProteomicsDB; 26892; -.
DR   ProteomicsDB; 74117; -. [Q8TCC7-1]
DR   ProteomicsDB; 74118; -. [Q8TCC7-2]
DR   ProteomicsDB; 74119; -. [Q8TCC7-3]
DR   Antibodypedia; 28883; 215 antibodies from 27 providers.
DR   DNASU; 9376; -.
DR   Ensembl; ENST00000336232.7; ENSP00000337335.2; ENSG00000149452.16. [Q8TCC7-1]
DR   Ensembl; ENST00000430500.6; ENSP00000398548.2; ENSG00000149452.16. [Q8TCC7-1]
DR   Ensembl; ENST00000535878.5; ENSP00000443368.1; ENSG00000149452.16. [Q8TCC7-5]
DR   Ensembl; ENST00000545207.5; ENSP00000441658.1; ENSG00000149452.16. [Q8TCC7-4]
DR   GeneID; 9376; -.
DR   KEGG; hsa:9376; -.
DR   MANE-Select; ENST00000336232.7; ENSP00000337335.2; NM_004254.4; NP_004245.2.
DR   UCSC; uc001nwo.4; human. [Q8TCC7-1]
DR   AGR; HGNC:10972; -.
DR   CTD; 9376; -.
DR   DisGeNET; 9376; -.
DR   GeneCards; SLC22A8; -.
DR   HGNC; HGNC:10972; SLC22A8.
DR   HPA; ENSG00000149452; Group enriched (choroid plexus, kidney).
DR   MIM; 607581; gene.
DR   neXtProt; NX_Q8TCC7; -.
DR   OpenTargets; ENSG00000149452; -.
DR   PharmGKB; PA389; -.
DR   VEuPathDB; HostDB:ENSG00000149452; -.
DR   eggNOG; KOG0255; Eukaryota.
DR   GeneTree; ENSGT00940000154901; -.
DR   HOGENOM; CLU_001265_33_3_1; -.
DR   InParanoid; Q8TCC7; -.
DR   OMA; WWIPESI; -.
DR   OrthoDB; 2088942at2759; -.
DR   PhylomeDB; Q8TCC7; -.
DR   TreeFam; TF315847; -.
DR   PathwayCommons; Q8TCC7; -.
DR   Reactome; R-HSA-561048; Organic anion transport.
DR   Reactome; R-HSA-9793528; Ciprofloxacin ADME.
DR   SignaLink; Q8TCC7; -.
DR   BioGRID-ORCS; 9376; 17 hits in 1153 CRISPR screens.
DR   GeneWiki; SLC22A8; -.
DR   GenomeRNAi; 9376; -.
DR   Pharos; Q8TCC7; Tclin.
DR   PRO; PR:Q8TCC7; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q8TCC7; protein.
DR   Bgee; ENSG00000149452; Expressed in pigmented layer of retina and 64 other tissues.
DR   ExpressionAtlas; Q8TCC7; baseline and differential.
DR   Genevisible; Q8TCC7; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008514; F:organic anion transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015132; F:prostaglandin transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0005452; F:solute:inorganic anion antiporter activity; IDA:UniProtKB.
DR   GO; GO:0006811; P:monoatomic ion transport; IEA:UniProtKB-KW.
DR   GO; GO:0015732; P:prostaglandin transport; IDA:UniProtKB.
DR   GO; GO:0009636; P:response to toxic substance; IEA:UniProtKB-KW.
DR   GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL.
DR   Gene3D; 1.20.1250.20; MFS general substrate transporter like domains; 1.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR036259; MFS_trans_sf.
DR   InterPro; IPR004749; Orgcat_transp/SVOP.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   PANTHER; PTHR24064; SOLUTE CARRIER FAMILY 22 MEMBER; 1.
DR   PANTHER; PTHR24064:SF439; SOLUTE CARRIER FAMILY 22 MEMBER 8; 1.
DR   Pfam; PF00083; Sugar_tr; 1.
DR   SUPFAM; SSF103473; MFS general substrate transporter; 1.
DR   PROSITE; PS50850; MFS; 1.
DR   TIGRFAMs; TIGR00898; 2A0119; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Detoxification; Glycoprotein;
KW   Ion transport; Lipid transport; Membrane; Phosphoprotein;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..542
FT                   /note="Organic anion transporter 3"
FT                   /id="PRO_0000273439"
FT   TOPO_DOM        1..9
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        10..30
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        31..123
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        124..144
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        145..154
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        155..175
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        176
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        177..197
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        198..212
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        213..233
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        234..236
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        237..257
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        258..327
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        328..348
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        349..354
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        355..375
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        376..386
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        387..407
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        408..411
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        412..432
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        433..471
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        472..492
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        493..542
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   REGION          515..542
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         4
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1U7"
FT   CARBOHYD        86
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        102
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..345
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_022562"
FT   VAR_SEQ         1..123
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_045824"
FT   VAR_SEQ         1..91
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045272"
FT   VAR_SEQ         406..455
FT                   /note="DLQTVRTVLAVFGKGCLSSSFSCLFLYTSELYPTVIRQTGMGVSNLWTRV
FT                   -> GERLGLPQNPLEEAARLGARDFTAGSASKSLCYLEQVPALSGAQGLSSRK (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_022563"
FT   VAR_SEQ         456..542
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_022564"
FT   VAR_SEQ         510
FT                   /note="W -> WSVTASGPPR (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10049739"
FT                   /id="VSP_022565"
FT   VARIANT         129
FT                   /note="F -> L (in dbSNP:rs11568479)"
FT                   /id="VAR_030146"
FT   VARIANT         149
FT                   /note="R -> S (complete loss of function;
FT                   dbSNP:rs45566039)"
FT                   /evidence="ECO:0000269|PubMed:16291576"
FT                   /id="VAR_030147"
FT   VARIANT         260
FT                   /note="I -> R (complete loss of function;
FT                   dbSNP:rs11568493)"
FT                   /evidence="ECO:0000269|PubMed:16291576"
FT                   /id="VAR_030148"
FT   VARIANT         277
FT                   /note="R -> W (reduced function; dbSNP:rs11568492)"
FT                   /evidence="ECO:0000269|PubMed:16291576"
FT                   /id="VAR_030149"
FT   VARIANT         281
FT                   /note="V -> A (in 6% of African-Americans;
FT                   dbSNP:rs45438191)"
FT                   /id="VAR_030150"
FT   VARIANT         305
FT                   /note="I -> F (in 3.5% of Asian-American; reduced function;
FT                   dbSNP:rs11568482)"
FT                   /evidence="ECO:0000269|PubMed:16291576"
FT                   /id="VAR_030151"
FT   VARIANT         389
FT                   /note="A -> V (in dbSNP:rs749944923)"
FT                   /evidence="ECO:0000269|PubMed:12811365"
FT                   /id="VAR_030152"
FT   VARIANT         448
FT                   /note="V -> I (in dbSNP:rs11568486)"
FT                   /id="VAR_030153"
FT   CONFLICT        150
FT                   /note="Missing (in Ref. 1; AAD19357)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        151
FT                   /note="P -> T (in Ref. 1; AAD19357)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        271
FT                   /note="K -> E (in Ref. 2; BAB47393)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        286
FT                   /note="Missing (in Ref. 1; AAD19357)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        411
FT                   /note="R -> E (in Ref. 1; AAD19357)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        478..480
FT                   /note="YGI -> FTGS (in Ref. 1; AAD19357)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        526
FT                   /note="A -> T (in Ref. 3; BAG60589)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   542 AA;  59856 MW;  22799360D91B4CCF CRC64;
     MTFSEILDRV GSMGHFQFLH VAILGLPILN MANHNLLQIF TAATPVHHCR PPHNASTGPW
     VLPMGPNGKP ERCLRFVHPP NASLPNDTQR AMEPCLDGWV YNSTKDSIVT EWDLVCNSNK
     LKEMAQSIFM AGILIGGLVL GDLSDRFGRR PILTCSYLLL AASGSGAAFS PTFPIYMVFR
     FLCGFGISGI TLSTVILNVE WVPTRMRAIM STALGYCYTF GQFILPGLAY AIPQWRWLQL
     TVSIPFFVFF LSSWWTPESI RWLVLSGKSS KALKILRRVA VFNGKKEEGE RLSLEELKLN
     LQKEISLAKA KYTASDLFRI PMLRRMTFCL SLAWFATGFA YYSLAMGVEE FGVNLYILQI
     IFGGVDVPAK FITILSLSYL GRHTTQAAAL LLAGGAILAL TFVPLDLQTV RTVLAVFGKG
     CLSSSFSCLF LYTSELYPTV IRQTGMGVSN LWTRVGSMVS PLVKITGEVQ PFIPNIIYGI
     TALLGGSAAL FLPETLNQPL PETIEDLENW SLRAKKPKQE PEVEKASQRI PLQPHGPGLG
     SS
//
